4//SEC Filing
Alexza Pharmaceuticals Inc. 4
Accession 0001209191-16-128996
CIK 0001344413operating
Filed
Jun 20, 8:00 PM ET
Accepted
Jun 21, 3:42 PM ET
Size
27.6 KB
Accession
0001209191-16-128996
Insider Transaction Report
Form 4
PAKIANATHAN DEEPIKA
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2016-06-21−11,606→ 0 totalExercise: $4.68From: 2013-06-21Exp: 2023-05-20→ Common Stock (11,606 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−3,991→ 0 totalExercise: $3.50From: 2012-07-06Exp: 2022-06-06→ Common Stock (3,991 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−12,500→ 0 totalExercise: $1.28From: 2016-06-03Exp: 2025-06-22→ Common Stock (12,500 underlying) - Disposition from Tender
Common Stock
2016-06-21−658→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−625→ 0 totalExercise: $35.20From: 2010-06-18Exp: 2020-05-18→ Common Stock (625 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−3,125→ 0 totalExercise: $15.30From: 2011-08-28Exp: 2021-07-28→ Common Stock (3,125 underlying) - Disposition from Tender
Common Stock
2016-06-21−98,967→ 0 total(indirect: See footnote)
Footnotes (3)
- [F1]Per the terms of the Agreement and Plan of Merger, dated 5/9/16, among the Issuer, Grupo Ferrer Internactional, S.A. and Ferrer Pharma Inc. (the "Agreement) and the Offer (as defined in the Agreement), each share of the Issuer's common stock was tendered for $0.90 per share in cash, without interest and less any required withholding taxes, plus one contractual contingent value right per share ("CVR") (as defined in the Agreement).
- [F2]97,988 shares are held directly by Delphi Ventures VI, L.P. ("DV VI") and 979 shares are held directly by Delphi BioInvestments VI, L.P. ("DBI VI" together with DV VI, the "Delphi VI Funds"). Delphi Management Partners VI, LLC ("DMP VI") is the general partner of each of DV VI and DBI VI and may be deemed to have beneficial ownership of the shares held by such entities. The Reporting Person is a managing member of DMP VI and may be deemed to share voting and dispositive power over the shares held by the Delphi VI Funds. The Reporting Person disclaims beneficial ownership of shares held by the Delphi VI Funds except to the extent of any pecuniary interest therein.
- [F3]Disposed of per Section 3.4(a) of the Agreement, whereby each option that was outstanding immediately prior to the Offer Closing (as defined in the Agreement) was cancelled without consideration.
Documents
Issuer
Alexza Pharmaceuticals Inc.
CIK 0001344413
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001344413
Filing Metadata
- Form type
- 4
- Filed
- Jun 20, 8:00 PM ET
- Accepted
- Jun 21, 3:42 PM ET
- Size
- 27.6 KB